Psychiatry & Neurology Doctors in Marysville, KS Accepting Medicare
1 Psychiatry & Neurology doctors found. Showing 1 - 1
 Steven Eshelman, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 406 N 3rd St Ste 3, Marysville, KS 66508 Phone: 785-562-7805 Fax: 785-561-3930 |
News Archive
Anesthetic-loaded liposomes can delay onset of neuropathic pain
Using tiny spheres filled with an anesthetic derived from a shellfish toxin, researchers at Boston Children's Hospital and the Massachusetts Institute of Technology have developed a way to delay the rise of neuropathic pain, a chronic form of pain that arises from flawed signals transmitted by damaged nerves.
Medco Health Solutions to acquire United BioSource Corporation
Medco Health Solutions, Inc. and United BioSource Corporation today announced a definitive agreement under which Medco will acquire closely held UBC in an all-cash transaction valued at approximately $730 million. The combination of America's leading advanced pharmacy with one of the world's most respected sources of post-approval drug and device research extends Medco's core capabilities in data analytics and research to further accelerate pharmaceutical knowledge – advancing patient safety and furthering evidence-based medicine.
New Pediatric Physical Medicine and Rehabilitation Service at NewYork-Presbyterian Hospital
NewYork-Presbyterian Hospital has established a Pediatric Physical Medicine and Rehabilitation Service, led by Dr. Heakyung Kim. In this role, Dr. Kim will provide specialized care for children with neuromuscular disorders and other special needs at the Hospital's two major centers for pediatric care: Morgan Stanley Children's Hospital at NewYork-Presbyterian Hospital/Columbia University Medical Center and the Komansky Center for Children's Health at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
NovaBay first-quarter net loss increases to $1.6 million
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported financial results for the first quarter of 2010.
Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
› Verified 7 days ago